

Pharmaceuticals and Medical Devices Agency

This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Summary of investigation results Caspofungin acetate

April 20, 2017

Non-proprietary name

Caspofungin acetate

Brand name (Marketing authorization holder)

Cancidas for Intravenous Drip Infusion 50 mg and 70 mg (MSD K.K.)

Indications

- 1. Febrile neutropenia suspected of a fungal infection
- 2. The following fungal infections due to Candida or Aspergillus
 - Esophageal candidiasis
 - Invasive candidiasis
 - Aspergillosis (invasive aspergillosis, chronic necrotizing pulmonary aspergillosis, pulmonary aspergilloma)

Summary of revision

"Toxic epidermal necrolysis" and "oculomucocutaneous syndrome" should be added in the Clinically Significant Adverse Reactions section.

Background of the revision and investigation results

Cases of toxic epidermal necrolysis or oculomucocutaneous syndrome have been reported in patients treated with caspofungin acetate both in Japan and overseas. CCDS* has been revised as well as the United States and European package inserts. Following an investigation result based on the opinions of expert advisors and the available evidence, the MHLW/PMDA concluded that revision of the package insert was necessary.

The number of reported adverse reactions and fatal cases in the last 3 fiscal years in Japan

No case associated with toxic epidermal necrolysis has been reported. One case

Pharmaceuticals and Medical Devices Agency Office of Safety I 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: safety.info@pmda.go.jp



Pharmaceuticals and Medical Devices Agency

This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

associated with oculomucocutaneous syndrome has been reported (including no cases for which a causal relationship to the product could not be ruled out). No fatality has been reported.

NOTE:

*CCDS is prepared by the marketing authorization holder and covers material relating to safety, indications, dosing, pharmacology, and other information concerning the product.

Pharmaceuticals and Medical Devices Agency Office of Safety I 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: <u>safety.info@pmda.go.jp</u>